DOCSLIB.ORG

WO 2012/039887 Al 2400 0

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 29 March 2012 (29.03.2012) WO 2012/039887ft Al (51) International Patent Classification: (72) Inventors; and A61L 15/58 (2006.01) A61L 26/00 (2006.01) (75) Inventors/Applicants (for US only): ZHANG, Jinzhong [US/US]; 7 Soho Circle, Pittsford, NY 14534 (US). (21) International Application Number: WARD, Keith, W . [US/US]; 5340 Lincoln Road, On PCT/US201 1/049266 tario, NY 145 19 (US). LOPEZ, Francisco, J. [ES/US]; (22) International Filing Date: 70 Barchan Dune Rise, Victor, NY 14564 (US). 26 August 201 1 (26.08.201 1) JONASSE, Matthew [US/US]; 1190 Scandia Drive, Webster, NY 14580 (US). (25) Filing Language: English (74) Agents: VO, Toan, P. et al; BAUSCH & LOMB IN (26) Publication Language: English CORPORATED, One Bausch & Lomb Place, Rochester, (30) Priority Data: NY 14604-2701 (US). 61/384,754 2 1 September 2010 (21 .09.2010) US (81) Designated States (unless otherwise indicated, for every 13/217,336 25 August 201 1 (25.08.201 1) US kind of national protection available): AE, AG, AL, AM, (71) Applicant (for all designated States except US): AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, BAUSCH & LOMB INCORPORATED [US/US]; One CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, Bausch & Lomb Place, Rochester, NY 14604-2701 (US). DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, [Continued on next page] (54) Title: COMPOSITION AND METHOD FOR PROMOTING WOUND HEALING (57) Abstract: A composition for promoting wound healing comprises a bioadhesive polymer and a pharmaceutically ac 2400 ceptable liquid medium. Such a composition is applied to a wound to promote healing of the wound. The bioadhesive polymer can be selected from the group consisting of natural O or synthetic hydrophilic polymers and hydrogels. 0 FIG. 6 w o 2012/039887 Ai III III II II III III I llll III II I lllll II I II ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, GW, ML, MR, NE, SN, TD, TG). TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Declarations under Rule 4.17: — as to the identity of the inventor (Rule 4A7(i)) (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, Published: GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, — with international search report (Art. 21(3)) ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, COMPOSITION AND METHOD FOR PROMOTING WOUND HEALING BACKGROUND The present invention relates to a composition and method for promoting wound healing. In particular, the present invention relates to a composition comprising a bioadhesive polymer, and a method using such composition, for healing wounds. The process of wound healing involves a highly orchestrated series of biological responses to tissue injury, including proliferation, migration, and extracellular matrix 1-5 deposition . In the cornea, wound recovery begins with epithelial cell migration, which 6 occurs independent of epithelial cell proliferation until the wounded area is closed . Thereafter, the thickness of the epithelial layer is recovered with a combination of new cell proliferation and movement of cells into the new epithelial layer from the basal layer. While in vitro models can recapitulate most of these individual processes, and can be informative in the study of wound healing from a mechanistic point of view, such a complex process can best be studied in vivo, and there are numerous available 7-9 literature examples of relevant corneal wound healing models . Antimicrobial agents have been used to help the wound healing process have been used. However, there is still a need to provide simple, non-toxic, easy-to-use materials to assist wound healing. SUMMARY In general, the present invention provides a composition comprising a bioadhesive polymer for use to promote wound healing, and a method for healing wound by applying such a composition to a wound. A bioadhesive polymer is a natural or synthetic polymer that has a property of adhering to a biological surface upon being applied thereto. In one aspect, a composition of the present invention comprises a bioadhesive polymer and a pharmaceutically acceptable vehicle. In another aspect, a composition of the present invention comprises a bioadhesive polymer and a pharmaceutically acceptable vehicle, wherein the bioadhesive polymer comprises a mucoadhesive adhesive, and the pharmaceutically acceptable vehicle comprises a liquid medium. The term "mucoadhesive polymer" means a natural or synthetic polymer that has a property of adhering to a mucosal surface upon being applied thereto In still another aspect, a composition of the present invention comprises a bioadhesive polymer and a pharmaceutically acceptable vehicle, wherein the bioadhesive polymer comprises a mucoadhesive polymer, and the pharmaceutically acceptable vehicle comprises a liquid medium. In yet another aspect, a composition of the present invention comprises a bioadhesive polymer and a pharmaceutically acceptable vehicle, wherein the bioadhesive polymer comprises a mucoadhesive polymer, and the pharmaceutically acceptable vehicle comprises an aqueous medium. The term "aqueous medium" means a medium comprising water, and optionally other materials, which may be soluble in water or in another material included in such medium. In a further aspect, the present invention provides a method for promoting wound healing, the method comprising applying to a wound a composition that comprises a bioadhesive polymer and a pharmaceutically acceptable vehicle, wherein the pharmaceutically acceptable vehicle comprises an aqueous medium. Other features and advantages of the present invention will become apparent from the following detailed description and claims and the appended drawings. DESCRIPTION OF THE DRAWINGS Fig. 1. Representative images showing the process of corneal reepithelialization in the Besivance® group. Slit-lamp photographs were taken after instillation of topical fluorescein drops. Image acquired immediately following surgery (Left), 36 hours post- surgery (Middle), and 72 hours post-surgery (Right), respectively. The dotted ring (Left or Middle) surrounding the fluorescein-labeled area represents the wound area of the cornea. Fig. 2 . Representative histochemical sections of the rabbit cornea stained with hematoxylin and eosin. Image on the left shows a multilayered epithelium acquired from an unwounded area of the cornea from an animal in the saline group. The image in the middle shows an unclosed corneal defect at 72 hours from an animal in the Vigamox® group. The arrow points to the epithelial front as the wound is healing. The image on the ght shows the closed wound from an animal in the Besivance® group at 72 hours post- surgery, exhibiting a reduced number of corneal cell layers as compared with the intact epithelium shown in the left panel. Scale bar, 50 µητι . Fig. 3. Besivance® and other fluoroquinolones do not affect corneal wound area in a rabbit wound healing model. Data are means ± SEM, n=10 per group. Data were analyzed by a two-way ANOVA with repeated measures followed by the Tukey-Kramer test on data elevated to the power 0.6 prior to statistical analysis. Fig. 4 . Integrated effects of Besivance® and other fluoroquinolones on the corneal wound area in a rabbit wound healing model. Integrated responses were analyzed by calculating the areas under the curve using the trapezoidal rule for each treatment over the time course. Data are means ± SEM, n=10 per group. Data were analyzed by a one-way ANOVA followed by the Tukey-Kramer test on raw data. Fig. 5. DuraSite® reduces wound area in a rabbit wound healing model. Data are means ± SEM, n=10 per group. Data were analyzed by a two-way ANOVA with repeated measures followed by the Tukey-Kramer test on data elevated to the power 0.6 prior to statistical analysis. Represents time points at which the DuraSite® group was significantly different from the saline group. P < 0.05.. Fig. 6. Integrated effects of 100 ppm BAK, DuraSite®, Durasite® + 100 ppm BAK, and AzaSite®on wound area in a rabbit wound healing model. Integrated responses were analyzed by calculating the areas under the curve using the trapezoidal rule for each treatment over the time course. Data are means ± SEM, n=10 per group. Data were analyzed by a one-way ANOVA followed by the Tukey-Kramer test on raw data. * vs. Saline; P < 0.05. Fig. 7. BAK does not affect corneal wound area in a rabbit wound healing model. Data are means ± SEM. n=10 per group. Data were analyzed by a two-way ANOVA with repeated measures followed by the Tukey-Kramer test on data elevated to the power 0.6 prior to statistical analysis. Fig. 8. Integrated effects of BAK on wound area in a rabbit wound healing model. Integrated responses were analyzed by calculating the areas under the curve using the trapezoidal rule for each treatment over the time course. Data are means ± SEM, n=10 per group. Data were analyzed by a one-way ANOVA followed by the Tukey-Kramer test on raw data. DETAILED DESCRIPTION In one aspect, a composition of the present invention comprises a bioadhesive polymer and a pharmaceutically acceptable vehicle.
Recommended publications
  • Pharmaceutical Appendix to the Tariff Schedule 2

    Pharmaceutical Appendix to the Tariff Schedule 2

    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
  • Marrakesh Agreement Establishing the World Trade Organization

    Marrakesh Agreement Establishing the World Trade Organization

    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
  • (12) United States Patent (10) Patent No.: US 8,486,374 B2 Tamarkin Et Al

    (12) United States Patent (10) Patent No.: US 8,486,374 B2 Tamarkin Et Al

    USOO8486374B2 (12) United States Patent (10) Patent No.: US 8,486,374 B2 Tamarkin et al. (45) Date of Patent: Jul. 16, 2013 (54) HYDROPHILIC, NON-AQUEOUS (56) References Cited PHARMACEUTICAL CARRIERS AND COMPOSITIONS AND USES U.S. PATENT DOCUMENTS 1,159,250 A 11/1915 Moulton 1,666,684 A 4, 1928 Carstens (75) Inventors: Dov Tamarkin, Maccabim (IL); Meir 1924,972 A 8, 1933 Beckert Eini, Ness Ziona (IL); Doron Friedman, 2,085,733. A T. 1937 Bird Karmei Yosef (IL); Alex Besonov, 2,390,921 A 12, 1945 Clark Rehovot (IL); David Schuz. Moshav 2,524,590 A 10, 1950 Boe Gimzu (IL); Tal Berman, Rishon 2,586.287 A 2/1952 Apperson 2,617,754 A 1 1/1952 Neely LeZiyyon (IL); Jorge Danziger, Rishom 2,767,712 A 10, 1956 Waterman LeZion (IL); Rita Keynan, Rehovot (IL); 2.968,628 A 1/1961 Reed Ella Zlatkis, Rehovot (IL) 3,004,894 A 10/1961 Johnson et al. 3,062,715 A 11/1962 Reese et al. 3,067,784. A 12/1962 Gorman (73) Assignee: Foamix Ltd., Rehovot (IL) 3,092.255. A 6, 1963 Hohman 3,092,555 A 6, 1963 Horn 3,141,821 A 7, 1964 Compeau (*) Notice: Subject to any disclaimer, the term of this 3,142,420 A 7/1964 Gawthrop patent is extended or adjusted under 35 3,144,386 A 8/1964 Brightenback U.S.C. 154(b) by 1180 days. 3,149,543 A 9, 1964 Naab 3,154,075 A 10, 1964 Weckesser 3,178,352 A 4, 1965 Erickson (21) Appl.
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0078604 A1 Kanios Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2006/0078604 A1 Kanios Et Al

    US 20060078604A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0078604 A1 Kanios et al. (43) Pub. Date: Apr. 13, 2006 (54) TRANSDERMAL DRUG DELIVERY DEVICE Related U.S. Application Data INCLUDING AN OCCLUSIVE BACKING (60) Provisional application No. 60/616,861, filed on Oct. 8, 2004. (75) Inventors: David Kanios, Miami, FL (US); Juan A. Mantelle, Miami, FL (US); Viet Publication Classification Nguyen, Miami, FL (US) (51) Int. Cl. Correspondence Address: A 6LX 9/70 (2006.01) DCKSTEIN SHAPRO MORN & OSHINSKY (52) U.S. Cl. .............................................................. 424/449 LLP (57) ABSTRACT 2101 L Street, NW Washington, DC 20037 (US) A transdermal drug delivery system for the topical applica tion of one or more active agents contained in one or more (73) Assignee: Noven Pharmaceuticals, Inc. polymeric and/or adhesive carrier layers, proximate to a non-drug containing polymeric backing layer which can (21) Appl. No.: 11/245,180 control the delivery rate and profile of the transdermal drug delivery system by adjusting the moisture vapor transmis (22) Filed: Oct. 7, 2005 sion rate of the polymeric backing layer. Patent Application Publication Apr. 13, 2006 Sheet 1 of 2 US 2006/0078604 A1 Fis ZZZZZZZZZZZZZZZZZZZ :::::::::::::::::::::::::::::::: Patent Application Publication Apr. 13, 2006 Sheet 2 of 2 US 2006/0078604 A1 3. s s 3. a 3 : 8 g US 2006/0078604 A1 Apr. 13, 2006 TRANSIDERMAL DRUG DELVERY DEVICE 0008. In the “classic' reservoir-type device, the active INCLUDING AN OCCLUSIVE BACKING agent is typically dissolved or dispersed in a carrier to yield a non-finite carrier form, Such as, for example, a fluid or gel.
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued

    Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued

    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
  • Ehealth DSI [Ehdsi V2.2.1] European Commission

    Ehealth DSI [Ehdsi V2.2.1] European Commission

    MTC eHealth DSI [eHDSI v2.2.1] European Commission - Master Translation/Transcoding Catalogue Responsible : eHDSI Solution Provider PublishDate : Thu Jun 01 17:03:48 CEST 2017 © eHealth DSI eHDSI Solution Provider v2.2.1 Thu Jun 01 17:03:48 CEST 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.1 Thu Jun 01 17:03:48 CEST 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.1 Thu Jun 01 17:03:48 CEST 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73
  • Stembook 2018.Pdf

    Stembook 2018.Pdf

    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
  • (12) United States Patent (10) Patent No.: US 9,012.437 B2 Wong Et Al

    (12) United States Patent (10) Patent No.: US 9,012.437 B2 Wong Et Al

    US009012437B2 (12) United States Patent (10) Patent No.: US 9,012.437 B2 Wong et al. (45) Date of Patent: *Apr. 21, 2015 (54) IMPLANTS AND METHODS FOR TREATING 3,961,628 A 6, 1976 Arnold NFLAMMATION-MEDIATED CONDITIONS 38885 A 1947s s et al. tal www. orphammar et al. OF THE EYE 4,014,334 A 3, 1977 Theeuwes et al. 4,063,064 A 12/1977 Saunders et al. (71) Applicant: Allergan, Inc., Irvine, CA (US) 4,088,864 A 5/1978 Theeuwes et al. 4,144,317 A 3/1979 Higuchi et al. (72) Inventors: Vernon G. Wong, Menlo Park, CA (US); 4,180,646 A 12/1979 Choi et al. Mae W. L. Hu, Los Altos, CA (US) 4,186,184 A 1/1980 Zaffaroni s s 4,200,098 A 4/1980 Ayer et al. (73) Assignee: Allergan, Inc., Irvine, CA (US) 4,285,9874,201,210 A 8,5/1980 1981 ''g'sHughes al.et al. - 4,300,557. A 1 1/1981 Refojo et al. (*) Notice: Subject to any disclaimer, the term of this 4,304,765 A 12/1981 Shell et al. patent is extended or adjusted under 35 3.6575 A 3. E. SE al. U.S.C. 154(b) by 0 days. 4,451,254 A 5/1984 Diniusen et et al. al. This patent is Subject to a terminal dis- 4,474,451 A 10/1984 Mizokami claimer 4,478,818. A 10/1984 Shell et al. 4,494,274 A 1/1985 Thurlow 4,521,210 A 6/1985 Wong 4,668,506 A 5, 1987 Bawa (22) Filed: May 3, 2013 4,756,911.
  • Council of Europe Committee of Ministers (Partial

    Council of Europe Committee of Ministers (Partial

    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (82) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 2 June 1982 at the 348th meeting of the Ministers' Deputies and superseding Resolution AP (77) 1) AND APPENDIX containing the list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 31 October 1982 RESOLUTION AP (82) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION 1 (Adopted by the Committee of Ministers on 2 June 1982 at the 348th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands, the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969 and 5 May 1964, respectively, Considering that, under the terms of its Statute, the aim of the Council of Europe is to achieve a greater unity between its Members for the purpose of safeguarding and realising the ideals and principles which are their common heritage and facilitating their economic and social progress; Having regard to the
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes

    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes

    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
  • (12) United States Patent (10) Patent No.: US 9.289,396 B2

    (12) United States Patent (10) Patent No.: US 9.289,396 B2

    US009289.396 B2 (12) United States Patent (10) Patent No.: US 9.289,396 B2 DeVore et al. 45) Date of Patent: Mar. 22,9 2016 (54) COLLAGEN-BASED IMPLANTS FOR A647/42 (2006.01) SUSTAINED DELVERY OF DRUGS A619/00 (2006.01) A647/46 (2006.01) (75) Inventors: Dale P. Devore, Chelmsford, MA (US); A 6LX3/55.75 (2006.01) Bruce H. Dewoolfson, Vienna, VA (US); (52) U.S. Cl. Eliot Lazar, Orchard Park, NY (US) CPC ............. A6IK 9/7007 (2013.01); A61 K9/0024 (2013.01); A61 K9/0051 (2013.01); A61 K9/06 (73) Assignee: Euclid Systems Corporation, Herndon, (2013.01); A61 K3I/55.75 (2013.01); A61 K VA (US) 47/42 (2013.01); A61 K47746 (2013.01) (*)c Notice:- r Subject to any disclaimer,- the term of this (58) CPCField ......of Classification A61 K9/06; SearchA61 K47/46; A61K 3 1/5575 patent is extended or adjusted under 35 See application file for complete search histo U.S.C. 154(b) by 352 days. pp p ry. (56) References Cited (21) Appl. No.: 13/813,557 U.S. PATENT DOCUMENTS (22) PCT Filed: Aug. 1, 2011 5,219,895 A * 6/1993 Kelman ................. CO9J 189/06 (86). PCT No.: PCT/US2O11?046098 522.68 5,259.998 A * 1 1/1993 Reich et al. .................... 264/1.1 S371 (c)(1), 5,874,537 A 2f1999 Kelman et al. 6,261,547 B1 * 7/2001 Bawa et al. ................ 424/78.04 (2), (4) Date: Jan. 31, 2013 2009/028O158 A1 11/2009 Butuner et al. (87) PCT Pub.
  • Marrakesh Agreement Establishing the World Trade Organization

    Marrakesh Agreement Establishing the World Trade Organization

    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX